Macular telangiectasia type 1 managed with long-term aflibercept therapy

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

A 60-year-old man diagnosed with macular telangiectasia type 1 (MacTel 1) was treated for 3 years with monthly aflibercept (Eylea; Regeneron, Tarrytown, NY) and serially imaged with spectral-domain optical coherence tomography. When administered monthly, aflibercept appeared to have a beneficial effect on macular edema secondary to MacTel 1. Visual acuity preservation despite minimal chronic macular edema could be attributed to the lack of significant photoreceptor disruption.

Original languageEnglish (US)
Pages (from-to)593-595
Number of pages3
JournalOphthalmic Surgery Lasers and Imaging Retina
Volume47
Issue number6
DOIs
StatePublished - Jun 1 2016

ASJC Scopus subject areas

  • Ophthalmology
  • Surgery

Fingerprint Dive into the research topics of 'Macular telangiectasia type 1 managed with long-term aflibercept therapy'. Together they form a unique fingerprint.

  • Cite this